FOX Translator
No data currently available.
No data currently available.
Just like you never want to hear a doctor say "oops" in the operating room, you never want to see a going-concern statement
in a financial report about a company you own. Accountants throw these in when they've been over the books, talked to customers,
and checked the horoscopes and have concluded there is "substantial doubt" about a company's ability to remain in business.
In short, don't blame the accountants if the company files for bankruptcy protection.
You¿d reckon that a going-concern
statement would be enough to send investors running to the exits, but it's not. True, many large institutions automatically
bail when an existing company gets slapped with one of these, but many individuals (often wrongly) take a chance they know
more than the bean counters.
During the tech boom of the late 1990s, many companies actually went public even though they had been hit with going-concern statements. Many of those companies subsequently disappeared. Enough said.
Home
Monday, June 09, 2008
MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
Comtex
NEW YORK, June 9, 2008 /PRNewswire via COMTEX/ ----
SATELLITE FEED: Monday, June 9th, 2008 1:00 PM - 1:15 PM ET Galaxy 26 Transponder 24 C-Band Downlink Freq: 4180 H NEWS: LARGE, LONG-TERM VETERANS AFFAIRS DIABETES TRIAL (VADT) REVEALS IMPORTANT CARDIOVASCULAR SAFETY NEWS ON AVANDIA FORMAT: B-roll and Sound bites
ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2, contact information and more available at http://www.prnewswire.com/broadcast/33475/press.html
STORY SUMMARY:
At the 68th Scientific Sessions of the American Diabetes Association in San Francisco, CA, several studies were presented evaluating the impact of blood sugar control to reduce diabetes-related complications in patients.
VADT (Veterans Affairs Diabetes Trial), a large, long-term and independent outcomes study, evaluated whether intensive versus standard blood sugar control can reduce the incidence of major cardiovascular (CV) events associated with diabetes including heart attack, congestive heart failure and CV death.
According to news announced by the ADA, AVANDIA(R) (rosiglitazone maleate) was used in a majority of patients in the study and was not associated with increased deaths. These data are consistent with results from other long-term studies with AVANDIA.
The primary result of VADT did not show that intensive blood sugar control (HbA1c levels below 7%) had a statistically significant effect on reducing major CV events associated with diabetes. However, it was found that there was a favorable trend in reducing all CV events, except CV death, among the patients in the intensive arm. While the VADT did not meet its primary endpoint, it is critical that these results do not detract from what is already known about the benefits of long-term blood sugar control on other serious and potentially life-threatening complications of diabetes, such as kidney failure, blindness and amputation. VADT is an independent study sponsored by the Department of Veterans Affairs.
SOUNDBITES: -- Dr. Farhad Zangeneh, MD, FACP, FACE, assistant clinical professor of medicine at the George Washington University in Washington, DC and medical director at the Endocrine, Diabetes & Osteoporosis Clinic in Sterling, VA -- Type 2 diabetes patients B-ROLL INCLUDES: **Physician footage**Footage of type 2 diabetes patients **Footage of AVANDIA product** VIDEO PROVIDED BY: GlaxoSmithKline
SOURCE GlaxoSmithKline
Copyright (C) 2008 PR Newswire. All rights reserved
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
